Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""Tzogani, K"" wg kryterium: Autor


Tytuł :
Beyond maximum grade: modernising the assessment and reporting of adverse events in haematological malignancies
Autorzy :
Velikova, G
Thanarajasingam, G
Minasian, LM
Baron, F
Cavalli, F
De Claro, RA
Dueck, AC
El-Galaly, TC
Everest, N
Geissler, J
Gisselbrecht, C
Gribben, J
Horowitz, M
Ivy, SP
Jacobson, CA
Keating, A
Kluetz, PG
Krauss, A
Kwong, YL
Little, RF
Mahon, F-X
Matasar, MJ
Mateos, M-V
McCullough, K
Miller, RS
Mohty, M
Moreau, P
Morton, LM
Nagai, S
Rule, S
Sloan, J
Sonneveld, P
Thompson, CA
Tzogani, K
Van Leeuwen, FE
Villa, D
Wingard, JR
Wintrich, S
Seymour, JF
Habermann, TM
Pokaż więcej
Temat :
Hematology [Human health sciences]
Hématologie [Sciences de la santé humaine]
Źródło :
Beyond maximum grade: modernising the assessment and reporting of adverse events in haematological malignancies. Lancet. Haematology, 5, 563-598., United KingdomElsevier. (2018).
Opis pliku :
application/pdf
Tytuł :
EMA Review of Belantamab Mafodotin (Blenrep) for the Treatment of Adult Patients with Relapsed/Refractory Multiple Myeloma.
Autorzy :
Tzogani K; European Medicines Agency, Amsterdam, The Netherlands.
Penttilä K; Lääkealan turvallisuus- ja kehittämiskeskus, Fimea, Finland.; The Committee for Medicinal Products for Human Use (CHMP).
Lähteenvuo J; Lääkealan turvallisuus- ja kehittämiskeskus, Fimea, Finland.; The Committee for Medicinal Products for Human Use (CHMP).
Lapveteläinen T; Lääkealan turvallisuus- ja kehittämiskeskus, Fimea, Finland.; The Committee for Medicinal Products for Human Use (CHMP).
Lopez Anglada L; Agencia Española de Medicamentos y Productos Sanitarios, Madrid, Spain.; The Committee for Medicinal Products for Human Use (CHMP).
Prieto C; Agencia Española de Medicamentos y Productos Sanitarios, Madrid, Spain.; The Committee for Medicinal Products for Human Use (CHMP).
Garcia-Ochoa B; Agencia Española de Medicamentos y Productos Sanitarios, Madrid, Spain.; The Committee for Medicinal Products for Human Use (CHMP).
Enzmann H; Bundesinstitut für Arzneimittel und Medizinprodukte, Bonn, Germany.; The Committee for Medicinal Products for Human Use (CHMP).
Gisselbrecht C; Hospital Saint Louis, Paris, France.
Delgado J; European Medicines Agency, Amsterdam, The Netherlands.
Pignatti F; European Medicines Agency, Amsterdam, The Netherlands.
Pokaż więcej
Źródło :
The oncologist [Oncologist] 2021 Jan; Vol. 26 (1), pp. 70-76. Date of Electronic Publication: 2020 Nov 23.
Typ publikacji :
Journal Article; Multicenter Study; Randomized Controlled Trial
MeSH Terms :
Antineoplastic Agents, Immunological*/therapeutic use
Immunoconjugates*/therapeutic use
Multiple Myeloma*/drug therapy
Adult ; Antibodies, Monoclonal, Humanized/therapeutic use ; Humans
Czasopismo naukowe
Tytuł :
EMA Review of Daunorubicin and Cytarabine Encapsulated in Liposomes (Vyxeos, CPX-351) for the Treatment of Adults with Newly Diagnosed, Therapy-Related Acute Myeloid Leukemia or Acute Myeloid Leukemia with Myelodysplasia-Related Changes.
Autorzy :
Tzogani K; European Medicines Agency, Amsterdam, The Netherlands.
Penttilä K; Committee for Medicinal Products for Human Use (CHMP), Amsterdam, The Netherlands.; Finnish Medicines Agency, Fimea, Finland.
Lapveteläinen T; Committee for Medicinal Products for Human Use (CHMP), Amsterdam, The Netherlands.; Finnish Medicines Agency, Fimea, Finland.
Hemmings R; Committee for Medicinal Products for Human Use (CHMP), Amsterdam, The Netherlands.; Medicines and Healthcare Products Regulatory Agency, London, United Kingdom.
Koenig J; Committee for Medicinal Products for Human Use (CHMP), Amsterdam, The Netherlands.; Federal Institute for Drugs and Medical Devices, Bonn, Germany.
Freire J; Pharmacovigilance Risk Assessment Committee (PRAC), Amsterdam, The Netherlands.; INFARMED, IP, Lisboa, Portugal.
Márcia S; Pharmacovigilance Risk Assessment Committee (PRAC), Amsterdam, The Netherlands.; INFARMED, IP, Lisboa, Portugal.
Cole S; Committee for Medicinal Products for Human Use (CHMP), Amsterdam, The Netherlands.; Medicines and Healthcare Products Regulatory Agency, London, United Kingdom.
Coppola P; Committee for Medicinal Products for Human Use (CHMP), Amsterdam, The Netherlands.; Medicines and Healthcare Products Regulatory Agency, London, United Kingdom.
Flores B; Committee for Medicinal Products for Human Use (CHMP), Amsterdam, The Netherlands.; Medicines and Healthcare Products Regulatory Agency, London, United Kingdom.
Barbachano Y; Committee for Medicinal Products for Human Use (CHMP), Amsterdam, The Netherlands.; Medicines and Healthcare Products Regulatory Agency, London, United Kingdom.
Roige SD; European Medicines Agency, Amsterdam, The Netherlands.
Pignatti F; European Medicines Agency, Amsterdam, The Netherlands.
Pokaż więcej
Źródło :
The oncologist [Oncologist] 2020 Sep; Vol. 25 (9), pp. e1414-e1420. Date of Electronic Publication: 2020 Apr 13.
Typ publikacji :
Journal Article; Multicenter Study; Randomized Controlled Trial
MeSH Terms :
Leukemia, Myeloid, Acute*/drug therapy
Liposomes*
Adult ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Cytarabine/therapeutic use ; Daunorubicin ; Humans ; Ireland
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies